Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Chiara Paoli, Paola Guglielmelli, Francesco Mannelli, Miriam Borella, Vittorio Rosti, Elisa Rumi, Maria Chiara Finazzi, Oscar Borsani, Carmela Mannarelli, Maria Esposito, Mario Xhani, Lisa Pieri, Tiziano Barbui, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 6840–6841.

https://doi.org/10.1182/blood-2022-156566

Published: 2022

Journal Articles

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Huiling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

Blood (2017) 130 (15): 1768–1771.

https://doi.org/10.1182/blood-2017-02-765032

Published: 2017

Includes: Supplemental data

Journal Articles

Accessible Chromatin Landscape Reveals a Proliferative Osteoprogenitor Transcriptional Program in Bone Marrow Mesenchymal Stromal Cells from Patients with Primary Myelofibrosis

Christophe Desterke, PhD, Nadira Ruzehaji, PhD, Bernadette Guerton, Johanna Konopacki, MD, Solene-Florence Kammerer-Jacquet, MD, Alessandro M. Vannucchi, MD PhD, Lisa Pieri, MD PhD, Christophe Martinaud, MD PhD, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2016) 128 (22): 3135.

https://doi.org/10.1182/blood.V128.22.3135.3135

Published: 2016

Journal Articles

Prognotic Impact of Mutations in Systemic Mastocytosis

Lisa Pieri, MD PhD, Giada Rotunno, MSc, PhD, Francesca Gesullo, MSc, Tiziana Fanelli, MSc, Giuditta Corbizi Fattori, MSc, Annalisa Pacilli, PhD, Federica Scarfì, MD, Maria Loredana Iorno, MD, Fabio Almerigogna, MD, Roberto Salerno, MD, Paola Guglielmelli, MD PhD, Roberta Zanotti, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 1953.

https://doi.org/10.1182/blood.V128.22.1953.1953

Published: 2016

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Paola Guglielmelli, MD PhD, Giada Rotunno, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Daniela Pietra, PhD, Daniela Cilloni, MD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 351.

https://doi.org/10.1182/blood.V126.23.351.351

Published: 2015

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Alessandro Pancrazzi, BS, Tiziana Fanelli, MSc, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Marker Mahtab, Ana Rodriguez, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4087.

https://doi.org/10.1182/blood.V126.23.4087.4087

Published: 2015

Journal Articles

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Blood (2015) 126 (23): 2803.

https://doi.org/10.1182/blood.V126.23.2803.2803

Published: 2015

Journal Articles

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Hans Hasselbalch, MD, Lisa Pieri, MD PhD, Steffen Koschmieder, MD, Francisco Cervantes, Weichao Bao, PhD, Stacey Kalambakas, MD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Florian H. Heidel, MD

Blood (2015) 126 (23): 825.

https://doi.org/10.1182/blood.V126.23.825.825

Published: 2015

Journal Articles

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Elisa Rumi, MD, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Mario Cazzola, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1615.

https://doi.org/10.1182/blood.V126.23.1615.1615

Published: 2015

Journal Articles

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Annalisa Pacilli, PhD, Paola Guglielmelli, MD PhD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Rajmonda Fjerza, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1630.

https://doi.org/10.1182/blood.V126.23.1630.1630

Published: 2015

Journal Articles

JAK2 V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

Lisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Tiziana Fanelli, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Srdan Verstovsek, Alessandro M. Vannucchi

Blood (2015) 125 (21): 3352–3353.

https://doi.org/10.1182/blood-2015-01-624536

Published: 2015

Journal Articles

Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis

Blood (2014) 124 (21): 1856.

https://doi.org/10.1182/blood.V124.21.1856.1856

Published: 2014

Journal Articles

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

Blood (2014) 124 (21): 1867.

https://doi.org/10.1182/blood.V124.21.1867.1867

Published: 2014

Journal Articles

In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology

Tiziano Barbui, MD, Alessandra Carobbio, MSc, Elisa Rumi, MD, Guido Finazzi, MD, Heinz Gisslinger, MD, Francesco Rodeghiero, Maria Luigia Randi, MD, Alessandro Rambaldi, Bettina Gisslinger, MSc, Lisa Pieri, MD PhD, Irene Bertozzi, Ilaria Carola Casetti, MD, Leonhard Müllauer, MD, Animesh Pardanani, MBBS, PhD, Jürgen Thiele, MD PhD, Francesco Passamonti, MD, Alessandro M. Vannucchi, MD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 1822.

https://doi.org/10.1182/blood.V124.21.1822.1822

Published: 2014

Journal Articles

Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients

Blood (2014) 124 (21): 1824.

https://doi.org/10.1182/blood.V124.21.1824.1824

Published: 2014

Journal Articles

A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)

Blood (2014) 124 (21): 1826.

https://doi.org/10.1182/blood.V124.21.1826.1826

Published: 2014

Journal Articles

Endogenous TGF-beta1 Mediated Osteogenic Impairment of Medullar Mesenchymal Stromal Cells in Primary Myelofibrosis

Christophe Martinaud, MD, Christophe Desterke, PhD, Johanna Konopacki, MD, Lisa Pieri, MDPhD, Rachel Golub, PhD, Sandrine Schmutz, PhD, Adrienne Anginot, PhD, Bernadette Guerton, Nathalie Rochet, MD PhD, Patricia Albanese, PhD, Emilie Henault, Thierry De Revel, Marie-Françoise Bourgeade, PhD, Vanucchi Alessandro, MD, Jean-Jacques Lataillade, MD PhD, Marie-Caroline Le Bousse-Kerdilès, PhD

Blood (2014) 124 (21): 1873.

https://doi.org/10.1182/blood.V124.21.1873.1873

Published: 2014

Journal Articles

Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea

Srdan Verstovsek, MD PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Elisa Rumi, MD, Elisabetta Gattoni, MD, Lisa Pieri, MD PhD, Haifeng Zhang, PhD, Mario Cazzola, MD, Hagop M. Kantarjian, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1847.

https://doi.org/10.1182/blood.V124.21.1847.1847

Published: 2014

NARROW

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Accessible Chromatin Landscape Reveals a Proliferative Osteoprogenitor Transcriptional Program in Bone Marrow Mesenchymal Stromal Cells from Patients with Primary Myelofibrosis

Prognotic Impact of Mutations in Systemic Mastocytosis

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

JAK2 V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology

Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients

A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)

Endogenous TGF-beta1 Mediated Osteogenic Impairment of Medullar Mesenchymal Stromal Cells in Primary Myelofibrosis

Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only